Amniotic Fluid-Derived Stem Cells (AFSC) and Their Application in Cell Therapy and Tissue Engineering

Document Type : Review Article/ Systematic Review Article/ Meta Analysis

Authors

1 Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan

2 National Academy of Young Scientists, School of Biological Sciences, University of the Punjab, Lahore, Pakistan

3 Department of Biology, University of Veterinary and Animal Sciences, Lahore, Pakistan

4 Department of Neurosciences, School of Medical Sciences, University Sains Malaysia, Kelantan, Malaysia

Abstract

Context: Amniotic Fluid Derived Stem Cells (AFSC) has mesenchymal origin and is multipotent. Having played their role in the detection of genetic abnormalities in the unborn children, they are gaining attention in the regenerative medicine because of their pluripotency.
 
Evidence Acquisition: AFSCs possess great proliferating ability and have no ethical and religious issues in their use. AFSCs may also be studied for the stem cells differentiation such as production of multiple lineages of different cells like heart, liver, pancreas, etc. The potential of their use in regenerative medicine as well as their differentiation into multiple cells is possible.
 
Results: AFSCs have the potential to be used in tissue repair and regeneration of bladder and kidney injuries, for the treatment of congenital anomalies like tracheal anomalies and spina bifida therapy etc. However, like every therapeutic potential, AFSCs also have some limitations such as low rate of differentiation of transplanted AFSCs and immune rejection.
 
Conclusions: AFSCs have great therapeutic potential, but extensive research is warranted to overcome the limitations to use AFSC as therapy.

Keywords

Open Access Policy: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/

References

  1. 1.De Coppi P, Bartsch GJ, Siddiqui MM, Xu T, Santos CC, Perin L, et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol. 2007;25(1):100–6.

    1. Petsche Connell J, Camci-Unal G, Khademhosseini A, Jacot JG. Amniotic fluid-derived stem cells for cardiovascular tissue engineering applications. Tissue Eng Part B Rev. 2013;19(4):368–79.
    2. Jeffrey SD, Sherman E. Prenatal diagnostic testing.: Merck Manual; 2008.
    3. Atala A. Essentials of stem cells. In: Lanza JR, Gearhart B, Hogan D, Melton R, Pedersen ED, Thomas J, et al editors. Amniotic Fluidderived Pluripotent Cells. 2nd ed. Canada: Elsevier; 2009.
    4. Prusa AR, Marton E, Rosner M, Bernaschek G, Hengstschlager M. Oct-4-expressing cells in human amniotic fluid: a new source for stem cell research? Hum Reprod. 2003;18(7):1489–93.
    5. Guillot P, Moschidou D, Pascale VG. Reprogramming human amniotic fluid stem cells to functional pluripotency by manipulation of culture conditions.: Protocol Exchange; 2012. Available from: http:// www.nature.com/protocolexchange/protocols/2426.
    6. Zsebo KM, Williams DA, Geissler EN, Broudy VC, Martin FH, Atkins HL, et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell. 1990;63(1):213–24.
    7. Klemmt P. Application of amniotic fluid stem cells in basic science and tissue regeneration. Organogenesis. 2012;8(3):76.
    8. Phermthai T, Odglun Y, Julavijitphong S, Titapant V, Chuenwattana P, Vantanasiri C, et al. A novel method to derive amniotic fluid stem cells for therapeutic purposes. BMC Cell Biol. 2010;11:79.
    9. Tsai MS, Lee JL, Chang YJ, Hwang SM. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum Reprod. 2004;19(6):1450–6.
    10. De Coppi P, Callegari A, Chiavegato A, Gasparotto L, Piccoli M, Taiani J, et al. Amniotic fluid and bone marrow derived mesenchymal stem cells can be converted to smooth muscle cells in the cryo-injured rat bladder and prevent compensatory hypertrophy of surviving smooth muscle cells. J Urol. 2007;177(1):369–76.
    11. Tsai MS, Hwang SM, Tsai YL, Cheng FC, Lee JL, Chang YJ. Clonal amniotic fluid-derived stem cells express characteristics of both mesenchymal and neural stem cells. Biol Reprod. 2006;74(3):545–51. 13. Murphy SV, Atala A. Amniotic fluid and placental membranes: unexpected sources of highly multipotent cells. Semin Reprod Med. 2013;31(1):62–8.
    12. Dobreva MP, Pereira PN, Deprest J, Zwijsen A. On the origin of amniotic stem cells: of mice and men. Int J Dev Biol. 2010;54(5):761–77.
    13. Rosner M, Hengstschlager M. Amniotic fluid stem cells and fetal cell microchimerism. Trends Mol Med. 2013;19(5):271–2.
    14. Rodrigues MT, Lee SJ, Gomes ME, Reis RL, Atala A, Yoo JJ. Amniotic fluid-derived stem cells as a cell source for bone tissue engineering. Tissue Eng Part A. 2012;18(23-24):2518–27.
    15. Tajiri N, Acosta S, Glover LE, Bickford PC, Jacotte Simancas A, Yasuhara T, et al. Intravenous grafts of amniotic fluid-derived stem cells induce endogenous cell proliferation and attenuate behavioral deficits in ischemic stroke rats. PLoS One. 2012;7(8).
    16. Pan HC, Cheng FC, Chen CJ, Lai SZ, Lee CW, Yang DY, et al. Post-injury regeneration in rat sciatic nerve facilitated by neurotrophic factors secreted by amniotic fluid mesenchymal stem cells. J Clin Neurosci. 2007;14(11):1089–98.
    17. Pan HC, Yang DY, Chiu YT, Lai SZ, Wang YC, Chang MH, et al. Enhanced regeneration in injured sciatic nerve by human amniotic mesenchymal stem cell. J Clin Neurosci. 2006;13(5):570–5.
    18. Rehni AK, Singh N, Jaggi AS, Singh M. Amniotic fluid derived stem cells ameliorate focal cerebral ischaemia-reperfusion injury induced behavioural deficits in mice. Behav Brain Res. 2007;183(1):95–100.
    19. Kaviani A, Perry TE, Dzakovic A, Jennings RW, Ziegler MM, Fauza DO. The amniotic fluid as a source of cells for fetal tissue engineering. J Pediatr Surg. 2001;36(11):1662–5.
    20. Weber B, Emmert MY, Behr L, Schoenauer R, Brokopp C, Drogemuller C, et al. Prenatally engineered autologous amniotic fluid stem cell-based heart valves in the fetal circulation. Biomaterials. 2012;33(16):4031–43.
    21. Perin L, Sedrakyan S, Giuliani S, Da Sacco S, Carraro G, Shiri L, et al. Protective effect of human amniotic fluid stem cells in an immunodeficient mouse model of acute tubular necrosis. PLoS One. 2010;5(2).
    22. Carraro G, Perin L, Sedrakyan S, Giuliani S, Tiozzo C, Lee J, et al. Human amniotic fluid stem cells can integrate and differentiate into epithelial lung lineages. Stem Cells. 2008;26(11):2902–11.
    23. Anum SZ, Muzavir SR, Zafa H, Khan AA, Ahmad A. Stem Cells Therapy as Treatment for Spinal Cord Injury. Health. 2012;3(1):19–23.
    24. Sacco SD, Roger E, De Filippo RE, Perin L. Tissue Engineering and Regenerative Medicine. In: Sabine WG editor. : Advances in Regenerative Medicine; 2011.
    25. Perin L, Giuliani S, Jin D, Sedrakyan S, Carraro G, Habibian R, et al. Renal differentiation of amniotic fluid stem cells. Cell Prolif. 2007;40(6):936–48.
    26. Chiavegato A, Bollini S, Pozzobon M, Callegari A, Gasparotto L, Taiani J, et al. Human amniotic fluid-derived stem cells are rejected after transplantation in the myocardium of normal, ischemic, immuno-suppressed or immuno-deficient rat. J Mol Cell Cardiol. 2007;42(4):746–59.
    27. Bollini S, Cheung KK, Riegler J, Dong X, Smart N, Ghionzoli M, et al. Amniotic fluid stem cells are cardioprotective following acute myocardial infarction. Stem Cells Dev. 2011;20(11):1985–94.
    28. Hilfiker A, Kasper C, Hass R, Haverich A. Mesenchymal stem cells and progenitor cells in connective tissue engineering and regenerative medicine: is there a future for transplantation? Langenbecks Arch Surg. 2011;396(4):489–97.
    29. Saulnier N, Lattanzi W, Puglisi MA, Pani G, Barba M, Piscaglia AC, et al. Mesenchymal stromal cells multipotency and plasticity: induction toward the hepatic lineage. Eur Rev Med Pharmacol Sci. 2009;13 Suppl 1:71–8.
    30. Da Sacco S, Sedrakyan S, Boldrin F, Giuliani S, Parnigotto P, Habibian R, et al. Human amniotic fluid as a potential new source of organ specific precursor cells for future regenerative medicine applications. J Urol. 2010;183(3):1193–200.
    31. Moorefield EC, McKee EE, Solchaga L, Orlando G, Yoo JJ, Walker S, et al. Cloned, CD117 selected human amniotic fluid stem cells are capable of modulating the immune response. PLoS One. 2011;6(10).
    32. Zhang P, Baxter J, Vinod K, Tulenko TN, Di Muzio PJ. Endothelial differentiation of amniotic fluid-derived stem cells: synergism of biochemical and shear force stimuli. Stem Cells Dev. 2009;18(9):1299–308.
    33. Rennie K, Gruslin A, Hengstschlager M, Pei D, Cai J, Nikaido T, et al. Applications of amniotic membrane and fluid in stem cell biology and regenerative medicine. Stem Cells Int. 2012;2012:721538.
    34. Bailo M, Soncini M, Vertua E, Signoroni PB, Sanzone S, Lombardi G, et al. Engraftment potential of human amnion and chorion cells derived from term placenta. Transplantation. 2004;78(10):1439–48.
    35. Banas RA, Trumpower C, Bentlejewski C, Marshall V, Sing G, Zeevi A. Immunogenicity and immunomodulatory effects of amnion-derived multipotent progenitor cells. Hum Immunol. 2008;69(6):321–8.
    36. Brunstein CG, Wagner JE. Cord blood transplantation for adults. Vox Sang. 2006;91(3):195–205. 39. Fukuchi Y, Nakajima H, Sugiyama D, Hirose I, Kitamura T, Tsuji K. Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Stem Cells. 2004;22(5):649–58. Anum SZ et al. 6 Razavi Int J Med. 2015;3(1):e20135
    37. Rosner M, Schipany K, Shanmugasundaram B, Lubec G, Hengstschlager M. Amniotic fluid stem cells: future perspectives. Stem Cells Int. 2012;2012:741810.
    38. Rosner M, Dolznig H, Schipany K, Mikula M, Brandau O, Hengstschlager M. Human amniotic fluid stem cells as a model for functional studies of genes involved in human genetic diseases or oncogenesis. Oncotarget. 2011;2(9):705–12.
    39. Peister A, Woodruff MA, Prince JJ, Gray DP, Hutmacher DW, Guldberg RE. Cell sourcing for bone tissue engineering: amniotic fluid stem cells have a delayed, robust differentiation compared to mesenchymal stem cells. Stem Cell Res. 2011;7(1):17–27.
    40. Laurent LC, Ulitsky I, Slavin I, Tran H, Schork A, Morey R, et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell. 2011;8(1):106–18.
    41. Zhang S, Geng H, Xie H, Wu Q , Ma X, Zhou J, et al. The heterogeneity of cell subtypes from a primary culture of human amniotic fluid. Cell Mol Biol Lett. 2010;15(3):424–39.
    42. Roubelakis MG, Bitsika V, Zagoura D, Trohatou O, Pappa KI, Makridakis M, et al. In vitro and in vivo properties of distinct populations of amniotic fluid mesenchymal progenitor cells. J Cell Mol Med. 2011;15(9):1896–913.
    43. Kim YW, Kim HJ, Bae SM, Kim YJ, Shin JC, Chun HJ, et al. Time-course transcriptional profiling of human amniotic fluid-derived stem cells using microarray. Cancer Res Treat. 2010;42(2):82–94.
    44. Aurich H, Sgodda M, Kaltwasser P, Vetter M, Weise A, Liehr T, et al. Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. Gut. 2009;58(4):570–81.
    45. Soler R, Fullhase C, Hanson A, Campeau L, Santos C, Andersson KE. Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease. J Urol. 2012;187(4):1491–7.
Razavi International Journal of Medicine
Volume 3, Issue 1
January 2015
Pages 1-6

Files

Share

How to cite

Statistics